AMS (American Medical Systems) closes Ovion deal despite Conceptus first refusal action
This article was originally published in Clinica
American Medical Systems (AMS) announced on July 7 that it has completed its acquisition of female sterilisation technology firm Ovion, in defiance of an attempt by Ovion's rival, Conceptus, to exercise a right of first refusal. AMS and Ovion entered into the acquisition agreement on June 3, triggering a 30-day period during which Conceptus had the right to purchase Ovion instead. This was a condition of a previous intellectual property settlement.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.